Pay in 4 interest-free payments of $5.53 Learn more
Ships within 48 hours · Estimated delivery Sep 7 - Sep 12
If your study requires isolating the effects of just one peptide for a control arm, you should purchase the individual vials rather than the blend
Research Highlights Phase 1 (12 weeks): Reductions between ~2.6% and ~11.3% Phase 2 (48 weeks): Lower-dose groups reached ~9% reductions Higher-dose and titration groups achieved ~20% reductions Control groups saw ~0.4% These outcomes place Eloralintide among the strongest-performing compounds within the amylin-pathway category
- Los posibles efectos secundarios pueden incluir hipoglucemia, hinchazn, dolor en el lugar de la inyeccin y aumento del crecimiento de los tumores, si estn presentes
LCL161, an Oral Smac Mimetic/IAP Antagonist for Patients with Myelofibrosis (MF): Novel Translational Findings Among Long-Term Responders in a Phase 2 Clinical Trial
